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Abstract
Background and aims: Fatigue is one of the main symptoms of inflammatory bowel disease (IBD)
and is frequently reported by people in both active and quiescent disease. Many different
fatigue assessment scales have been used to measure fatigue, but none has been developed or
tested in IBD. This study aimed to develop a fatigue scale specific to the needs and experiences
of people with IBD.
Methods: A five-step sequential mixed method design was used: a qualitative phase to assess
patients' experience of fatigue and its impact on their lives, and four mixed qualitative–
quantitative phases to refine the scale and to assess its psychometric properties.
Results: 567 people participated in five phases. The resulting questionnaire has 3 sections: 5
questions assessing frequency and severity of fatigue; 30 questions rating the experience and
impact of fatigue; and a free-text section asking for patients' comments and additional issues
related to fatigue. Initial validation suggests that the questionnaire has good face and content
validity, acceptable to excellent test–retest stability (ICC 0.74 for Section 1 and 0.83 for Section
2) and a high degree of internal consistency (Cronbach's alpha N 0.9).
Conclusions: Participants in the study confirmed that fatigue in IBD is burdensome. Items
generated and refined by people with IBD-fatigue reflect their experience and form the basis ofllege London, Florence Nightingale School of Nursing, James Clerk Maxwell Building, 57 Waterloo Road,
.: +44 20 7848 3531; fax: +44 20 7848 3555.
han@kcl.ac.uk (W. Czuber-Dochan).
014.04.013
nd Colitis Organisation. Published by Elsevier B.V. Open access under CC BY-NC-ND license.
1399Development and psychometric testing of IBD-F patient self-assessment scalethis new IBD-fatigue scale, which is psychometrically robust with reliability estimates which fall
within statistically acceptable ranges. The scale can be used by patients and practitioners to
assess severity and impact of fatigue in people with IBD.
© 2014 European Crohn's and Colitis Organisation. Published by Elsevier B.V. All rights reserved.1. IntroductionFatigue is one of the most common symptoms experienced by
patients with inflammatory bowel disease (IBD).1,2 It is a major
problem, both when the disease is active and in remission, with
86% and 41% respectively reporting fatigue.3–5 Fatigue is one of
the leading concerns identified by people with IBD.2,6,7 The
symptom of fatigue in IBD has been described as subjective,
distressing and debilitating.1,4,8 It impacts on people's daily
functioning and affects their quality of life. 2,9 Fatigue has
been defined as a sense of continuing tiredness, with periods
of sudden and overwhelming lack of energy or a feeling of
exhaustion that is not relieved or fully relieved, following rest
or sleep. This definition is based onwork in cancer fatigue10 and
other chronic health conditions.11
The subjective and multifaceted nature of fatigue makes
it difficult to understand and measure. A recent systematic
review of literature looking at the description and manage-
ment of fatigue in IBD identified that limited attention has
been paid to the assessment and measurement of fatigue in
IBD.12 Eighteen studies included in the review attempted to
measure fatigue and nine different scales were used, with
many studies using more than one scale. The most frequently
employed scales were the Multidimensional Fatigue Invento-
ry (MFI, used in eight studies) and Fatigue Impact Scale (FIS,
used in seven studies). However the rationale for selecting
these or any other scales was not provided.12 All of the scales
were developed with either general populations or other
chronic conditions and none, except one scale (FACIT-F),13
had been previously tested with the IBD population. None has
been developed using the experience of people with IBD and
fatigue as the basis for questions.
A literature review on fatigue measurement scales in
chronic conditions identified 252 different scales published in
the past three decades.14 Another systematic review of scales
used in chronic disease-related fatigue evaluated the scales'
clinical and research utility, usability and the robustness of
psychometric properties and the authors concluded that there
were no scales that met the criteria of an ideal instrument.15
None of the scales were developed with the IBD population.
The most commonly used IBD quality of life scale includes
only one item on fatigue and one on energy.16,17 In previous
work undertaken with people with IBD and fatigue, they
reported IBD fatigue issues which were not covered in existing
fatigue scales.18 Also healthcare professionals have identified
the need for a comprehensive assessment tool specific to IBD
fatigue. 19
A fatigue assessment tool should be comprehensive,
accurate and reliable. To date there is no consensus on
which scale to use.14 Although fatigue has been reported as
having many similar characteristics across different chronic
conditions, the review concluded that no scale has been
found appropriate to measure fatigue in all disease groups. 20Therefore the conclusion has been drawn that a new fatigue
scale developed and tested with IBD population is required.
The aim of this study was to construct and validate a
self-assessment instrument to measure the multidimensional
nature of IBD-fatigue that takes into account the aspects of
fatigue most important to people with IBD. We also tested
two fatigue scales developed in other chronic conditions to
see if they would be reliable tools to measure IBD fatigue.
2. Materials and methods
A mixed method approach21 was used to develop a new
IBD-Fatigue (IBD-F) scale and to determine its quality and
validity. The process of developing and testing the IBD-F
questionnaire entailed five phases. 637 people volunteered,
in response to an advertisement in the Crohn's and Colitis UK
newsletter, to take part in phases 1–4. Phase 5 participants
were randomly selected by computer programme (alms.net.
database) from the Charity's membership database. All par-
ticipants received a Participant Information Sheet before
deciding to take part. Those selected for phases 1–4 pro-
vided written consent. Phase 5 participants provided implied
consent by returning completed questionnaires. Each par-
ticipant was involved in only one phase of the study.
2.1. Measurement tools
Across all phases demographic data were collected via a
short, self-completed questionnaire covering age, gender,
type of IBD and current fatigue level. Disease activity was
assessed by the Harvey–Bradshaw Index (HBI)22 for Crohn's
disease (CD) participants and the Simple Clinical Colitis
Activity Index (SCCAI) for participants with ulcerative colitis
(UC).23 Disease activity of 4 or below was classified as
remission and 5 and above was classed as active disease.
Fatigue was assessed by the Multidimensional Fatigue
Inventory (MFI), the Multidimensional Assessment of Fatigue
(MAF) and in the last two phases of the study (phase 4 and 5)
the newly developed IBD-F.
The MFI is a 20-item self-assessment instrument
designed to measure five dimensions of fatigue (physical
fatigue, mental fatigue, general fatigue, reduced activity
and motivation).24 Each dimension comprises four questions
with scores ranging from 4 to 20 per dimension, with higher
scores indicating greater fatigue. The MFI was included as,
although it has not been validated in IBD, it has been the
most frequently used scale to measure fatigue in IBD.12
The MAF scale25 incorporates 16 items and measures four
dimensions of fatigue: severity, distress, degree of interfer-
ence in activities of daily living, and timing. The scores
range from 1 (no fatigue) to 50 (severe fatigue), with higher
scores indicating a higher level of fatigue and its impact on
the individual. The MAF was included as it measures the
1400 W. Czuber-Dochan et al.severity, as well as the distress and impact of fatigue. These
aspects were often raised by patients with IBD and fatigue in
our preliminary work.18
Permission to use the MFI and MAF was obtained from the
authors and both scales were used in phases 2–5.
2.2. Methods
Development and testing of the IBD-F scale entailed five
phases.
2.2.1. Phase one: item generation
A qualitative study using unstructured in-depth interviews
with 20 participants self-reporting IBD-fatigue was conduct-
ed by a single researcher (WCD) to gain insight into the
experience of IBD-fatigue to determine if the MFI and MAF
scales reflected their experience and concerns with IBD
fatigue, and to identify items and questions for the new
scale. The unstructured interviews started with an open
question ‘Tell me about your experience of fatigue’, and
followed with reflective questioning seeking clarification
and further information when and if required.
The participants were purposively selected from volun-
teers to reflect diversity of characteristics including: age;
gender; diagnosis (UC or CD); time since diagnosis; fatigue
severity; and geographical location in the UK. The interviews
were audio recorded, transcribed verbatim and analysed
using Moustakas' method of data analysis.26 Data analysis
identified that all areas of concern in IBD fatigue were not
reflected in the existing MAF and MFI, and guided develop-
ment of the items and questions for the first draft of the
questionnaire, which was reviewed by the steering group
members consisting of a gastroenterologist, IBD nurse, nurse
academics, project researchers and lay members (co-authors).
Existing fatigue scales did not fully match the experience and
concerns of people with IBD fatigue and therefore develop-
ment of new scale specific to IBD fatigue was further justified.
2.2.2. Phase two: face and content validity
Participants were asked to complete the draft IBD-F ques-
tionnaire and were subsequently interviewed. Face-to-face
individual audio-recorded structured cognitive interviews
involving both ‘think aloud’ and verbal probing techniques
were conducted with 16 participants to refine questions, rank
items and test the response format.27 The goal of a cognitive
interview is to detect any problems in a questionnaire, and to
identify the cognitive process that respondents use to judge and
comprehend the questions, and make their decision on how to
respond.27 The interviewer encouraged participants to com-
ment on whether each question made sense and was relevant
to their experience, if they understood the question, and if
they would keep, change or remove the question from the
questionnaire. This stage tested face and content validity. Face
validity assessed if the questions seemed to measure what
they intended to measure and if they made sense to people
with IBD-fatigue. The clarity of each question was assessed by
testing if the questions were free of jargon and if the language
was easy to understand by the respondents, and that the
questionnaire was easy to complete.28 Changes in grammatical
structure and choice of words were made as suggested by
participants.Content validity ensures that a questionnaire reflects all
the main issues of importance to participants.28 Iterative
testing and analysis was employed: data generated (quali-
tative and quantitative) were analysed using a descriptive
matrix.29 Following a round of testing with the first eight
participants, the IBD-F questionnaire was modified accord-
ing to their comments, and the revised questionnaire was
further tested in a second round with eight participants and
further modifications were made. The project steering
group reviewed drafts by email and at face to face meetings.
Participants were also asked to complete and then
comment on the MFI and MAF scales, to determine which
scale (MFI, MAF or IBD-F) best reflected the patient's fatigue
and which scale they preferred to use and why.
2.2.3. Phase three: initial piloting
The second stage of cognitive interviews was conducted
face-to-face with 30 purposively selected participants. Two
response formats, numerical and a visual analogue scale were
tested. Different numerical response formats (0–10 and 0–4)
were tested. Participants were asked to complete the ques-
tionnaire and were subsequently interviewed. Interim analysis
was performed after 15 interviews. Further refinements to the
IBD-F scale were made as indicated by participants, and the
revised scale was further tested with 15 participants.
2.2.4. Phase four: reliability testing
A postal questionnaire was distributed twice (test–retest) to
the same population group within six weeks to 70 purpo-
sively selected participants with IBD-fatigue, with one
reminder letter for each round. This initial piloting was
undertaken to test for frequency and severity of experience
of fatigue and changes over time. Item analysis, stability and
reliability testing were performed. Agreement between the
two sets of scores was assessed using the intra-class
correlation (ICC) method. The values are from 0 to 1, with
1 being complete agreement between sets. A value between
0.8 and 0.9 is generally acceptable.30
2.2.5. Phase five: initial validity testing
Construct validity was tested to identify the extent to which
the scale captures the latent construct in terms of its relation-
ship with other variables. Three hundred responses from
people with IBD and fatigue were calculated to be sufficient
to estimate percentages of particular responses to questions
with 95% confidence intervals. Internal consistency was tested
using the Cronbach's alpha coefficient aiming for an alpha
of more than 0.7 between each question. To obtain the
required sample a computer generated random sampling frame
(alms.net.database) was used to select about 10% of the
Crohn's and Colitis UK database (n = 2131 participants out of
total 29,156 adult members). These people were approached
by post and asked to complete a short questionnaire assessing
their current level of fatigue and if they would like to take part
in the study. This initial questionnaire was returned by 605
participants, and all 605 were posted the draft IBD-F
questionnaire and other assessment tools (described earlier).
Throughout this paper categorical variables are sum-
marised by the number and percentage in each category,
normally distributed continuous variables are summarised
by the mean and standard deviation, while non-normally
1401Development and psychometric testing of IBD-F patient self-assessment scaledistributed variables are summarised by the median and
inter-quartile range.
2.3. Ethical considerations
The study was approved by the local university Ethics
Committee (Ref number: PNM/09/110-93).
3. Results
A total of 567 people with IBD participated in the study.
Demographic data for participants are shown in Table 1.
3.1. Validity
3.1.1. Content validity
Phase 1 interviews were conducted from September to
December 2010. The results of this phase clearly fell into three
themes: fatigue and its description, impact of fatigue, and
attributes of and ways of managing fatigue. The first draft IBD-F
scale consisted of 49 questions and was therefore divided into
three sections: section one asking about severity, frequency and
duration of fatigue (9 questions), section two asking about the
impact of fatigue on people's life (36 questions) and section
three asking about causes/attributes of fatigue and ways of
managing fatigue (4 questions). Section one and two questions
were scored on a 0–10 numerical scale (0 = no fatigue; 10 =
severe fatigue) and section three questions were free text. The
questionnaire was tested for content and face validity as
described in phases two and three. Phase two was completed
in November 2011–January 2012, and phase three was
completed in May–July 2012. Following data analysis in each
phase, the questionnairewas refined and the final questionnaire
comprises three sections: section one — fatigue severity and
frequency (5 questions), section two — fatigue impact on daily
activities (30 questions), and section three — additional
questions about fatigue and its duration (5 questions). SectionTable 1 Demographic data for study participants.
Variable Phase 1 Phase
Gender M = 10 M = 8
F = 10 F = 8
Age mean (SD) 48.8 54.3
(14.9) (18.0)
Condition CD = 11 CD =
UC = 9 UC =
Years since diagnosed (median/range) 9.4 (1–37) 14.4 (
Fatigue level* on the day mean (SD) 5.1 (1.6) 6.3 (2
Disease activity no (%)
CD in remission** 2 (18%) 3 (38%
CD active*** 9 (88%) 5 (62%
UC in remission** 2 (22%) 0 (0%)
UC active*** 7 (78%) 8 (100
Key: *Fatigue level measured on a numeric 0–10 scale; disease activity
Clinical Colitis Activity Index for UC. **Disease activity of 4 or below wa
classified as active disease.one and two questions are scored on 0–4 scale (0— no fatigue or
none of the time and 4 — severe fatigue or all of the time) and
section three questions are descriptive. See Appendix 1 for a
final version of the IBD-F scale.
People interviewed in phases 2 and 3 felt that the content
of the IBD-F questionnaire closely matched their experience
and was more attuned to their experience than the MAF
and MFI: ‘IBD-F scale gives more information, feels easier to
answer, it feels more tailored to the condition, it feels more
appropriate’; ‘questions are excellent’; ‘IBD-F scale is more
specific to IBD’; ‘in IBD-F scale the questions are clear and
relevant, covered emotional and physical aspects, they are
easy to score and easy to understand’.
3.1.2. Construct validity
Draft questions asked about fatigue, including ‘your fatigue
right now’, ‘in the past 7, 14 and 30 days’. Fatigue levels
‘right now’ and in the past 14 days were perceived as the
most suitable. Seven days was perceived as not offering a
sufficiently long period of time for some activities to take
place, and 30 days was considered too long for participants
to remember, thus risking recall bias. The questions in
section one initially referred to fatigue severity (lowest and
highest level of fatigue), frequency and duration assessed in
percentage of waking time. However many participants had
difficulty estimating percentages and it was changed to a
0–10 score. The questions in section two referred to fatigue
impact on daily activities on a 0–10 scale (0 = strongly
disagree and 10 = strongly agree with ‘not applicable’ (N/A)
for some of the questions). The questions were initially
written in both positive (I can do) and negative (I have
difficulty with) format; however most participants had
problems with double negative questions, which resulted in
mistakes being made. Participants expressed a preference
for the questions being worded as a ‘problem statement’ (I am
not able to) rather than a statement of their ability (I can do),
as they would like to get help from healthcare professionals in
the areas where they struggle.2 Phase 3 Phase 4
Test–retest
Phase 5
M = 15 M M = 18 M = 147 (32%)
F = 15 F = 18 F = 318 (69%)
49.8 46.8 56.9
(15.1) (13.8) (13.8)
8 CD = 16 CD = 19 CD = 301 (65%)
8 UC = 14 UC = 17 UC = 164 (35%)
4–38) 17.3 (3–49) 10.5 (3–38) 26.0 (1–60)
.3) 4.7 (2.7) 5.7 (2.2) 4.9 (2.7)
) 9 (56%) 6 (33%) 84 (31%)
) 7 (44%) 12 (67%) 188 (69%)
6 (43%) 3 (23%) 57 (43%)
%) 8 (57%) 10 (77%) 76 (57%)
was assessed by the Harvey–Bradshaw Index for CD and the Simple
s classified as remission and ***disease activity of 5 and above was
1402 W. Czuber-Dochan et al.The response options of 0–10was seen bymany as toowide a
range and respondents were not able to differentiate between
adjacent points on the scale (e.g. between fatigue at level 6 or
level 7). Many participants preferred 0–4 as a scoring option
and the number of scores was reduced to five (0–4) with 0 = no
fatigue or none of the time, 4 = severe fatigue or all of the
time. N/A (not applicable) option was added to six questions
identified as not always applicable to everyone.3.1.3. Reliability
Reliability of the questionnaire was tested through test and
retest in phase four (August–October 2012). In the test stage 48/
70 (68.6%) potential participants returned questionnaires; in theTable 2 Agreement between questions (Phase 4 test–retest).
Item number Item name
Section one
1.1 What is your fatigue level right now
1.2 What was your highest fatigue level in the past two
1.3 What was lowest fatigue level in the past two week
1.4 What was your average fatigue level in the past two
1.5 How much of your waking time have you felt fatigued in
– Total score
Section two
2.1 I had to nap during the day because of fatigue
2.2 Fatigue stopped me from going out to social events
2.3 I was not able to go to work or college because of fa
2.4 My performance at work or education was affected
2.5 I had problems concentrating because of fatigue
2.6 I had difficulty motivating myself because of fatigue
2.7 I could not wash or dress myself because of fatigue
2.8 I had difficulty with walking because of fatigue
2.9 I was unable to drive as much as I need to because o
2.10 I was not able to do as much physical exercise as I wante
2.11 I had difficulty continuing with my hobbies or interest
2.12 My emotional relationship with my partner was affe
2.13 My sexual relationship with my partner was affected
2.14 My relationship with my children was affected by fa
2.15 I was low in mood because of fatigue
2.16 I felt isolated because of fatigue
2.17 My memory was affected because of fatigue
2.18 I made mistakes because of fatigue
2.19 Fatigue made me irritable
2.20 Fatigue made me frustrated
2.21 I got words mixed up because of fatigue
2.22 Fatigue stopped me from enjoying life
2.23 Fatigue stopped me from having a fulfilling life
2.24 My self-esteem was affected by fatigue
2.25 Fatigue affected my confidence
2.26 Fatigue made me feel unhappy
2.27 I had difficulties sleeping at night because of fatigu
2.28 Fatigue affected my ability to do normal household
2.29 I had to ask others for help because of fatigue
2.30 Quality of my life was affected by fatigue
– Total score
Key: * indicates the questions where N/A applies. This may partly explretest 41/48 questionnaires were returned (one participant died
and 6 did not respond to the second mailing). Five participants
were excluded as they changed from remission to active disease
or vice versa on the HBI or SCCAI between the test and retest.
This left 36 patients for inclusion in the analysis. The aim of the
analysis was to assess the repeatability of the IBD-F scale and to
compare this with equivalent values for the MFI and MAF.
Agreement between the test and retest questionnaires
was also examined for individual items of the IBD-F. For the
purposes of analyses, individual items were considered to be
continuous in nature. Agreement between the test and
retest measurements is shown in Table 2. There were few
missing items and most questions with less than 36 responses
were those with a N/A option.Number of subjects
with 2 measurements
ICC (95% CI)
36 0.47 (0.17, 0.69)
weeks 36 0.70 (0.49, 0.84)
s 36 0.45 (0.16, 0.69)
weeks 36 0.66 (0.44, 0.81)
the past two weeks 35 0.71 (0.50, 0.84)
36 0.74 (0.54, 0.86)
36 0.57 (0.30, 0.75)
35 0.75 (0.57, 0.87)
tigue 26* 0.77 (0.56, 0.89)
by fatigue 24* 0.74 (0.49, 0.88)
36 0.78 (0.61, 0.88)
36 0.68 (0.46, 0.82)
35 0.42 (0.11, 0.66)
35 0.69 (0.47, 0.83)
f fatigue 30* 0.67 (0.42, 0.83)
d to because of fatigue 34 0.88 (0.78, 0.94)
s because of fatigue 36 0.66 (0.43, 0.81)
cted by fatigue 27* 0.53 (0.20, 0.75)
by fatigue 23* 0.70 (0.42, 0.86)
tigue 20* 0.67 (0.34, 0.85)
35 0.66 (0.43, 0.81)
36 0.65 (0.41, 0.80)
36 0.71 (0.50, 0.84)
35 0.60 (0.35, 0.78)
36 0.74 (0.55, 0.86)
35 0.79 (0.62, 0.89)
36 0.71 (0.50, 0.84)
35 0.81 (0.66, 0.90)
36 0.78 (0.61, 0.88)
35 0.68 (0.45, 0.82)
36 0.80 (0.64, 0.89)
35 0.72 (0.51, 0.85)
e 36 0.72 (0.52, 0.85)
activities 36 0.59 (0.33, 0.77)
35 0.79 (0.63, 0.89)
36 0.83 (0.69, 0.91)
35 0.83 (0.69, 0.91)
ain the low response rate for the questions.
Table 3 Fatigue scores for test–retest obtained by other
fatigue scales.
Score N. subjects with
2 measurements
ICC (95% CI)
MFI — general fatigue 34 0.65 (0.46, 0.83)
MFI — physical fatigue 34 0.77 (0.60, 0.88)
MFI — reduced activity 35 0.78 (0.61, 0.88)
MFI — reduced motivation 34 0.81 (0.66, 0.90)
MFI — mental fatigue 35 0.84 (0.71, 0.92)
MAF 35 0.74 (0.55, 0.86)
Key: MFI — Multidimensional Fatigue Inventory; MAF — Multidi-
mensional Assessment of Fatigue.
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tween the two measurements of the individual questions in
both sections. However, the agreement for the total scores
was higher with an ICC value of 0.74 for Section 1 and 0.83
for Section 2. Agreement between the test and retest
measurements for the other fatigue scales is summarised in
Table 3.
Generally there was not excellent agreement between
repeat measurements for any of the scores.
3.1.4. Convergent validity
Phase 5 took place in January–May 2013. 605 people
were sent the questionnaire, 465 responded (77%). The
association between the IBD-F questionnaire Sections 1 and 2
total score and the other fatigue questionnaires was
examined using Pearson correlation. The IBD-F correlation
coefficient with the MAF was 0.73 (Section 1) and 0.78
(p b 0.001) (Section 2) and with the 5 subscales of the MFI
ranged between 0.47 and 0.65 (all p b 0.001), indicating
moderate correlation with established generic fatigue
scales.
3.1.5. Internal consistency
Internal consistency of the IBD-F and the other question-
naires was calculated using the Cronbach's alpha value:
for Section 1 it was 0.91; for Section 2 it was 0.98. This
compares favourably with the other fatigue scores: the MAF
Cronbach's alpha was 0.87 and for the 5 scales of the MFI it
ranged from 0.69 to 0.84.
3.1.6. Factor analysis
The final analyses examined the relationship between the
different components of the IBD-F score by performing a
factor analysis of each of the two sections of the question-
naire. Where more than one factor was deemed important, a
varimax rotation was performed to aid the interpretation
of the factor loadings. Factor loadings of 0.4 or higher were
required for an individual item to load to each factor. For
Section 1 all factors contributed fairly equally to the main
component (factor loadings 0.81–0.93). For Section 2, one
component dominated, explaining 63% of the total variation
in the data. A second component explained only 5% of the
total variation. As the first component was so dominant it
was decided by the steering group that no subscales within
Section 2 were warranted by the data and to keep Section 2
as a single “impact of fatigue” score.3.1.7. Item reduction and development of a scoring system
In Section 1, fatigue ‘now’ was the most unstable item, but
the steering group decided to keep this as an introductory
question which made sense to people and was easy to
answer. Therefore all five items were retained giving a
possible score of 0–20 for fatigue severity in Section 1
(Cronbach's alpha 0.91).
Some questions in Section 2 had high rates of ‘not
applicable’ (N/A) (e.g. relationship with children and sexual
relationship) but were felt during interviews to be very
important where they were applicable, and so were
retained. Some had relatively low stability in test–retest
(e.g. ability to perform normal household activities) but
were likewise felt to be very important where they applied.
Other items appeared superficially similar (e.g. irritability
and frustration, low in mood or unhappy) but scored
differently and so appear to be capturing different aspects
of the experience and were retained. Looking at the data in
detail, none of the 30 items tested were obvious candidates
for removal. As Section 2 of the questionnaire had good
overall internal consistency (Cronbach's alpha 0.98) and the
whole questionnaire fits easily onto 4 landscape pages, it
was decided to retain all items, pending further evaluation
of psychometric properties including sensitivity to change in
the future.31
The IBD-F Section 2 with no N/A answers selected can be
scored by adding the scores for all 30 questions. Where N/A
answers have been selected, the total score for Section 2
can be calculated by the formula:
Adjustedscore ¼ Actualscore
= 120−number NAs 4ð Þ  120:
This score for Section 2 gives a global estimation of the
impact of fatigue on the individual over the past 2 weeks.
3.1.8. Clinical utility
In testing, the questionnaire was positively received by
patients who commented on clear instructions on how to
complete it. Time to complete the final version took a
median of 10 min. Examples of written comments provided
by participants were: ‘easy to use and easy to relate to’, ‘it
is well thought through, it covers all areas of life’, ‘easy to
read, understand and complete’, ‘good format’, ‘good range
of answers’, ‘questions are excellent, and ‘allowed me to
best express how fatigue impacts on me’.
Positive response to the IBD-F scale was reflected by a
high response rate for postal questionnaire at 77%, with only
0.2–5.5% missing items. The highest missing values (from 3.6
to 5.5%) were observed for questions 3, 4, 9, 12, 13 and 14 in
Section 2, where the N/A option applied. It is possible that
some respondents instead of selecting N/A left the box
unchecked.
Of the three fatigue scales tested, IBD-F scale was the
scale preferred by the participants, as the MFI and MAF
scales were seen as ‘too simplistic and more generic’, and
not reflecting the full picture of their experience of fatigue.
The final version of the IBD-F scale is provided as a
supplement in Appendix 1. Online and PDF versions are also
available from www.fatigueinibd.co.uk. The online version
has an automatic scoring programme.
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Figure 1 Distribution of Section 1 IBD-F scores: phase 5.
1404 W. Czuber-Dochan et al.3.1.9. Reported fatigue results
The distribution of the Sections 1 and 2 total scores in phase
5 respondents is shown in Figs. 1 and 2 respectively.
Section 1 scores a maximum of 20; Section 2 a maximum of
120.
Disease activity in phase 5 respondents for both CD and
UC and its relation to the IBD fatigue score is reported in
Table 4. Fatigue score and impact were higher in active
disease than in remission for both CD and UC.
4. Discussion
The IBD-F scale consists of items generated specifically from
the issues of importance to people with IBD fatigue and it has
been found on initial testing to be valid and reasonably
reliable. The scale has not demonstrated excellent stability.
Fatigue and impact scores were, as would be expected,
higher in active disease than in remission, however with a
wide range of scores. Some people reported maximum
fatigue in remission while other reported no fatigue in
active flare. Participants with CD reported higher levels of
fatigue and impact than UC participants. However, only
moderate correlation between scores over time is likely to
reflect the variable nature of fatigue reported by many0
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Figure 2 Distribution of Section 2 IBD-F scores: phase 5.study participants during interviews. They reported that
fatigue is often highly variable, unpredictable and not
always related to disease activity, varying day by day and
even hour by hour. The items and the wording of the
questionnaire have been developed with the close engage-
ment of patients at each stage. Patient reported outcome
measures developed with patients and focusing on what
is important to them are increasingly recommended as
best practice for both clinical practice and research
purposes.32,33 The strength of the IBD-F scale lies in the
robust and rigorous scale development process, grounded in
the experience of fatigue as reported by patients.
IBD fatigue is a complex, multifaceted concept that
impacts on people's lives in varying ways and it can be
affected by many factors; therefore measuring fatigue
severity in isolation would not provide a full picture of
how fatigue affects people. The newly developed IBD-F
scale allows assessment of severity and frequency of fatigue
(Section 1); impact of fatigue (Section 2); and factors
contributing to it (Section 3). It allows full and comprehen-
sive assessment of an individual person as a prelude to
planning care specific to the individual's requirements.
The length of the questionnaire, four pages with a total of
40 questions, was seen by participants to provide a detailed
assessment, but short enough not to discourage completion.
A lengthy questionnaire is not always desirable,34 impacting
on use by patients and clinicians.20 Clear instructions for
use, acceptable time to complete (average 10 min), and
free access meet many characteristics of a desirable
scale.35,36
Fatigue scores obtained by the newly developed, disease
specific IBD-F self-assessment scale correlated reasonably
well with the existing fatigue measures (MFI and MAF)
developed with other diseases and had similar stability
overtime (Table 3).
This was the first study validating the use of these scales
with people with IBD. The MFI and MAF performed well on
our test–retest and were well correlated with the new
questionnaire, and so are also suitable for use in IBD.
However our study participants had a clear preference for
the new IBD-F scale.
Healthcare practitioners have identified the need for
systematic assessment of IBD fatigue.19 This tool will
contribute to recognition of fatigue and to its assessment.
However, treatment options, other than management of
inflammation and anaemia, are currently limited. 12,19 There
is a need to develop and test fatigue interventions for people
with IBD.5. Limitations
A possible limitation of the study is that all participants were
members of Crohn's and Colitis UK, and they may not
necessarily be representative of the entire IBD population;
however they were similar in age and disease duration to the
general IBD population.37,38 Additionally, the fact that the
participants were members of the charity meant that we
had no access to their clinical test results to verify IBD
disease activity or other related factors such as anaemia. In
future studies it would be beneficial to use clinical markers
for disease activity. Despite the sample for phase 5 being
Table 4 Disease activity for CD and UC and its relation to the IBD fatigue score.
Patient group Subgroup N Median (IQR) Range
IBD fatigue score — Section I***
Crohn's Remission 82 9 (6,11) (0, 19)
Patients(⁎) Active infl. 177 11 (9,14) (0, 20)
Colitis Remission 55 8 (5,11) (0, 16)
Patients(⁎⁎) Active infl. 74 11 (8,13) (0, 20)
IBD fatigue impact score — Section II****
Crohn's Remission 80 20 (8,38) (0, 119)
Patients(⁎) Active infl. 176 43 (25, 65) (0, 110)
Colitis Remission 54 18 (5, 41) (0, 72)
Patients(⁎⁎) Active infl. 73 39 (23, 51) (0, 120)
(*)41 Crohn's patients omitted as no CDAI score to categorise patient.
(**)35 Crohn's patients omitted as no UCAI score to categorise patient.
(***)Section I fatigue total scores 0–20.
(****)Section II fatigue impact total scores 0–120.
1405Development and psychometric testing of IBD-F patient self-assessment scalerandomly generated, participants were more likely to be
female and have CD rather than UC. This may be explained
by the makeup of the Crohn's and Colitis membership
database — 63% of members are female and two thirds
have CD.
Further testing and evaluation of the IBD-F is needed
before full psychometric validation is attained. Sensitivity to
change has not been assessed. It might also be useful to
define cut-off scores for clinically important fatigue levels.
6. Conclusion
We recognise that further development work is needed on
this questionnaire and the possibility of item reduction in
view of high Cronbach's alpha indicating some redundancy.
IBD-F scale cannot differentiate between fatigue resulting
from IBD and other co-morbidities, medication, or psycho-
logical status such as depression, which is recognised to be
high in IBD. However, our results suggest that the scale can
be used both for clinical research, to increase our body of
knowledge regarding fatigue, as well as for clinical practice
in the evaluation of a patient's fatigue and its impact.
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